We are translating the needs assessment and concept ideation into development of a minimal viable product. Our conversations with patients and providers with the Veterans Affairs provided a foundation for learning about the current state of affairs for Veterans with mental illness. In pitching our idea at the University of Southern California Center for Body Computing Conference, we spoke with players in research, military, legal, investors, and potential pilot partners.
, B.S. Arts, Technology, and the Business of Innovation
Advanced Degree(s): B.S. Arts, Technology, and the Business of Innovation
Mollitiam serves to aid veterans in navigating their journey for mental wellness. The platform helps patients improve their adherence to treatment and will use data to educate patients on their current wellbeing. This data collection will also empower the patient to have more in-depth discussions with their providers to ensure their treatment plan is right for them.
Mollitiam supports providers in the delivery and adjustment of therapeutic alliance. The platform supports the qualitative physician interviews with quantitative metrics to empower the patient’s conversation with providers to support effective clinical decision making. Between brick and mortar appointments, the platform brings a static treatment plan to life allowing for dynamic adjustments in resilience exercises.
Veterans Affairs faces $4-6B in costs for PTSD and Major Depressive Disorder patients and has the opportunity to save $1.7B by providing evidence-based treatment (RAND). In general, health costs of Veterans with PTSD/Depression cost 3.5-4x compared to the rest of the population. Mollitiam provides a cost-effective scalable opportunity to improve mental wellness of veterans and improve costs.
Mollitiam has started conversations with a rideshare company to explore the potential of a partnership to discuss further support of veterans’ reintegration into the civilian workforce. Mollitiam looks forward to furthering the conversation of aligning mental wellness of veterans integration into society.
Our main projected milestone is development of the minimal viable product in Q1 of 2018 and to begin the beta pilot with the Veterans Affairs in Q2 of 2018.
Mollitiam offers a comprehensive platform with to develop an unmatched psychobiometric profile of resilience and will be focused on a veteran-centric design approach.
The main barrier to market entry is clinical validation for approval for use within the Veterans Affairs.
We are engaged in exploratory conversations with clinical and industry partners.